Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

0.3077 +0.0409 (+15.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc

< Previous 1 2 3 Next >
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Via ACCESSWIRE
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Via ACCESSWIRE
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Via ACCESSWIRE
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Via ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Via ACCESSWIRE
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
Via ACCESSWIRE
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Aptevo Participating in the BIO International Convention
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
Via ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
Via ACCESSWIRE
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
Via ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Via ACCESSWIRE
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
Via ACCESSWIRE
Aptevo to Present at Bio-Europe Conference
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
Via ACCESSWIRE
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.